Traws Pharma
TRAW
17 hedge funds and large institutions have $2.27M invested in Traws Pharma in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
48% more capital inflows, than outflows
Capital inflows: $2.17M | Capital outflows: $1.46M
31% more funds holding
Funds holding: 13 → 17 (+4)
5.19% more ownership
Funds ownership: 39.41% → 44.59% (+5.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.84M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$257K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.6K |
| 4 |
Renaissance Technologies
New York
|
+$15.5K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$2.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$934K |
| 2 |
TCP
Tyndall Capital Partners
New York
|
-$452K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$48K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$29.3K |
TRAW Hedge Fund Activity: Q3 2019 in Review
17 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2019, worth a combined $2.27M — down 66% from $6.74M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TRAW positions and 1 closed out — a net gain of 4 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.84M. The largest seller was 683 Capital Management, cutting an estimated $934K.
- 17 institutional investors held Traws Pharma (TRAW) as of Q3 2019, up from 13 in Q2 2019.
- Funds reported $2.27M of Traws Pharma stock for Q3 2019, down 66% quarter-over-quarter.
- 5 funds opened new Traws Pharma positions in Q3 2019 and 1 closed out, a net change of +4 holders.
- The largest Traws Pharma buyer in Q3 2019 was Sabby Management, an estimated $1.84M added.
- The largest Traws Pharma seller in Q3 2019 was 683 Capital Management, an estimated $934K sold.
Based on aggregated 13F filings for Q3 2019.